Inventor · disambiguated record
Ryan Faucette
Also filed as: FAUCETTE RYAN
18 granted patents·7 pending applications·79 citations·filing 2006–2024
92Inventor score
Top patents by PatentIndex Score
25 records- 0195US11084884B2Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedemaTAKEDA PHARMACEUTICALS CO·Filed 2015·Granted Aug 10, 2021·23 cites·17 claims
- 0293US11340237B2Metabolite biomarkers for diseases associated with the contact activation systemTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted May 24, 2022·7 cites·26 claims
- 0392US10914747B2Immunoassay to detect cleaved high molecular weight kininogenDYAX CORP·Filed 2016·Granted Feb 9, 2021·6 cites·50 claims
- 0491US7687608B2Methods for reducing the mitogenicity of lectin compositionsSMARTCELLS INC·Filed 2006·Granted Mar 30, 2010·21 cites·11 claims
- 0590US11372002B2Assays for determining plasma kallikrein system biomarkersTAKEDA PHARMACEUTICALS CO·Filed 2014·Granted Jun 28, 2022·9 cites·15 claims
- 0689US11458477B2Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activationTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Oct 4, 2022·1 cites·20 claims
- 0787US11156612B2Methods of determining levels of cleaved and/or intact kininogenTAKEDA PHARMACEUTICALS CO·Filed 2014·Granted Oct 26, 2021·6 cites·15 claims
- 0886US10870115B2Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activationDYAX CORP·Filed 2016·Granted Dec 22, 2020·2 cites·20 claims
- 0984US2025199014A1Metabolite biomarkers for diseases associated with the contact activation systemTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 1083US12384854B2Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedemaTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Aug 12, 2025·1 cites·15 claims
- 1183US11826758B2Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activationTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Nov 28, 2023·0 cites·20 claims
- 1282US11668718B2Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWKTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jun 6, 2023·2 cites·14 claims
- 1381US2025172567A1Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwkTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 1480US12135329B2Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWKTAKEDA PHARMACEUTICALS CO·Filed 2023·Granted Nov 5, 2024·0 cites·17 claims
- 1577US12188948B2Metabolite biomarkers for diseases associated with the contact activation systemTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Jan 7, 2025·0 cites·18 claims
- 1677US2024142468A1Protein biomarkers for diseases associated with the contact activation systemTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 1775US12442824B2Assays for determining plasma kallikrein system biomarkersTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Oct 14, 2025·0 cites·9 claims
- 1875US2024271211A1Rna biomarkers for hereditary angioedemaTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 1974US8729242B2Methods for reducing the mitogenicity of lectin compositionsLANCASTER THOMAS M·Filed 2010·Granted May 20, 2014·1 cites·24 claims
- 2071US12493047B2Cleaved high molecule weight kininogen (HMWK) antibodies and methods of usingTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Dec 9, 2025·0 cites·4 claims
- 2164US2022170936A1Evaluation and treatment of bradykinin-mediated disordersTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
- 2262US11884979B2RNA biomarkers for hereditary angioedemaTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Jan 30, 2024·0 cites·26 claims
- 2362US11815516B2Protein biomarkers for diseases associated with the contact activation systemTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted Nov 14, 2023·0 cites·18 claims
- 2456US2024294623A1Tgf-beta inhibitors and therapeutic use thereofSCHOLAR ROCK INC·Filed 2022·Application pending·0 cites
- 2554US2025282857A1Tgf-beta inhibitors and use thereofSCHOLAR ROCK INC·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ryan Faucette files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →